Bd ceo tom polen addresses fda 510(k) clearance of bd alaris™ infusion system

Franklin lakes, n.j. , july 24, 2023 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx) chairman, ceo and president tom polen issued the following message regarding the u.s. food and drug administration (fda) 510(k) clearance for the updated bd alaris™ infusion system: "hello, i'm tom polen, chairman, ceo and president of bd.
BDX Ratings Summary
BDX Quant Ranking